Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a phase 3 trial. Caplyta ...
Johnson & Johnson has agreed to take over Intra-Cellular Therapies in a deal worth up to $14.6 billion – the second biopharma M&A announcement today. The $132-per-share agreement comes a few months ...
Consumer Reports uses data to compile an annual list of the most reliable new car brands. Some brands on the list are obvious while others are moving up reliability rankings. Reliability is a huge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback